MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s12185-019-02714-x

Медицинская библиотека · International journal of hematology · 2019

Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia.

Hasegawa Daisuke, Yoshimoto Yuri, Kimura Shunsuke, Kumamoto Tadashi, Maeda Naoko, Hara Junichi, Kikuta Atsushi, Kada Akiko, Kimura Toshimi, Iijima-Yamashita Yuka, Saito Akiko M, Horibe Keizo, Manabe Atsushi, Ogawa Chitose

Клиническое исследование I фазыСтатьяПеревод пока не подготовлен

Аннотация

Outcomes of children treated for relapsed acute lymphoblastic leukemia (ALL) remain poor. Bortezomib (BZM), a proteasome inhibitor, has shown promising activity against lymphoid malignancies. We conducted a phase I study to evaluate the safety and tolerability of multidrug chemotherapy including BZM in Japanese children with relapsed ALL. Three of five children with relapsed ALL enrolled in the study between November 2014 and April 2016 were evaluated. BZM (1.3 mg/m2) was administered on days 8, 11, 15, and 18 of multidrug induction chemotherapy. Pharmacokinetic studies were performed. Age at study entry was 5, 7, and 7 years old, respectively. Two patients had hyperdiploid B-precursor ALL, and one had T cell ALL. Although all patients experienced grade 3-4 hematologic toxicity and grade 3 elevation of aminotransferases, no dose-limiting toxicities were observed. The maximum tolerated dose was defined as 1.3 mg/m2. Peripheral neuropathy and respiratory complications were not observed. Complete remission was achieved in all three patients. The mean maximum plasma concentration and area under the concentration-time curve was 74.0 ng/mL and 73.9 ng h/mL, respectively. Thus, adding BZM to 5-drug induction chemotherapy appears safe and well-tolerated in Japanese children with relapsed ALL.

Для цитирования: Hasegawa Daisuke, Yoshimoto Yuri, Kimura Shunsuke, Kumamoto Tadashi, Maeda Naoko, Hara Junichi, Kikuta Atsushi, Kada Akiko, Kimura Toshimi, Iijima-Yamashita Yuka, Saito Akiko M, Horibe Keizo, Manabe Atsushi, Ogawa Chitose. Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia.. International journal of hematology. 2019. DOI: 10.1007/s12185-019-02714-x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.